{"id":"W2898372506","doi":"10.1093/annonc/mdy284.014","title":"A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Internal medicine; Doubling time; Placebo; Oncology; Randomized controlled trial; Gynecology; Urology; Cancer; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001726522,0.001649058,0.002540829,0.000416193,0.0005420803,0.0007888585,0.0008592067,0.00134348,0.004820554],"category_scores_gemma":[0.001294691,0.0006232816,0.001320815,0.0004119657,0.001085192,0.000831531,0.0003775163,0.002133545,0.0008231947],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005264367,"about_ca_system_score_gemma":0.001801337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001351256,"about_ca_topic_score_gemma":0.003710394,"domain_scores_codex":[0.9995584,0.0002573965,0.00002495164,0.00007295106,0.00002935046,0.00005701321],"domain_scores_gemma":[0.9993528,0.0001672675,0.000147099,0.00004733609,0.00005013686,0.0002353316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9735454,0.007141729,0.0005828184,0.0008950796,0.000753994,0.00003905004,0.0000587902,0.000264477,0.003643048,0.00009856233,0.001019042,0.01195799],"study_design_scores_gemma":[0.9684557,0.0294763,0.0009686731,0.00002268395,0.0002254965,0.00001831286,0.00001193147,0.000122461,0.0002363875,0.00006414703,0.0003912671,0.000006581478],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9731293,0.00757213,0.001358648,0.0006637718,0.000636134,0.01002369,0.002921056,0.0002286261,0.003466637],"genre_scores_gemma":[0.9665127,0.006286905,0.004151942,0.00181198,0.0004380996,0.01323796,0.002539065,0.00005281863,0.004968599],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004820554,"threshold_uncertainty_score":0.01612639,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08967654066231087,"score_gpt":0.426299160825572,"score_spread":0.3366226201632611,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}